Reply: Oxaliplatin- Or Irinotecan-Based Chemotherapy for Metastatic Colorectal Cancer in the Elderly

British Journal of Cancer - United Kingdom
doi 10.1038/sj.bjc.6601807
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Nature

Related search

Capecitabine and Irinotecan as First- Line Chemotherapy for Patients With Metastatic Colorectal Cancer

Journal of IMAB - Annual Proceeding (Scientific Papers)
Dentistry
2011English

Adjuvant Oxaliplatin- Or Irinotecan-Containing Chemotherapy Improves Overall Survival Following Resection of Metachronous Colorectal Liver Metastases

International Journal of Colorectal Disease
Gastroenterology
2010English

Irinotecan-Based Combination Chemotherapy for Metastatic Small Intestinal Adenocarcinoma

Oncology Letters
Cancer ResearchOncology
2010English

Phase I Trial of Oxaliplatin Plus S-1 Chemotherapy in Patients With Metastatic Colorectal Cancer

Oncology Letters
Cancer ResearchOncology
2010English

Bevacizumab May Overcome Clinical Tumor Drug Resistance to Irinotecan Based Chemotherapy in Patients With Metastatic Colorectal Cancer: Case Report

The Open Colorectal Cancer Journal
2010English

Oxaliplatin Plus Irinotecan Compared With Irinotecan Alone as Second-Line Treatment After Single-Agent Fluoropyrimidine Therapy for Metastatic Colorectal Carcinoma

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2008English

Outcomes of Third-Line Docetaxel-Based Chemotherapy in Advanced Gastric Cancer Who Failed Previous Oxaliplatin-Based and Irinotecan-Based Chemotherapies

Cancer Research and Treatment
Cancer ResearchOncology
2012English

Reply: Capecitabine and Bevacizumab as First-Line Treatment in Elderly Patients With Metastatic Colorectal Cancer

British Journal of Cancer
Cancer ResearchOncology
2010English

Clinical Significance of UGT1A1 Gene Polymorphisms on Irinotecan-Based Regimens as the Treatment in Metastatic Colorectal Cancer

OncoTargets and Therapy
OncologyPharmacology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy